Information Provided By:
Fly News Breaks for October 21, 2019
XAIR
Oct 21, 2019 | 16:25 EDT
Oppenheimer analyst Suraj Kalia initiated coverage of Beyond Air with an Outperform rating and $9 price target. The analyst views the company's plasma arc discharge inhaled nitric oxide technology as "early stage but highly disruptive." He sees "multiple call options" in several therapeutic segments for Beyond Air. If the LungFit device gets Premarket Approval Application in the second half of 2020, it bodes well for share gains from Mallinckrodt and for regulatory approval in other therapeutic indications, says the analyst.
News For XAIR From the Last 2 Days
There are no results for your query XAIR